Integra Lifesciences Holdings Corp represents a set of values and a corporate philosophy that focuses on making a positive impact in the field of healthcare. The company is committed to delivering innovative solutions and technologies, aiming to improve patient outcomes and quality of life. Integra Lifesciences Holdings Corp is guided by principles of integrity, transparency, and collaboration, fostering strong partnerships with healthcare professionals and stakeholders. With a dedication to continuous improvement, the company strives to provide advanced medical devices, regenerative technologies, and specialty products that enhance the lives of patients worldwide. Integra Lifesciences Holdings Corp prioritizes patient-centricity and is dedicated to making a difference in the global healthcare community.

Integra Lifesciences Holdings Corp is primarily present in various countries and regions worldwide. These include the United States, Europe, Asia-Pacific, and Latin America.

Integra Lifesciences Holdings Corp has attained several significant milestones. The company achieved FDA clearance for its DermaTran wound dressing, providing advanced wound care solutions. Additionally, Integra Lifesciences received CE Mark approval for its CUSA Clarity Ultrasonic Surgical Aspirator, enhancing surgical precision and patient outcomes. The company also introduced Codman Enterprise 2 Coil System, an advancement in endovascular treatment for brain aneurysms. Furthermore, Integra Lifesciences acquired Medtronic's MicroFrance and Xomed Surgical Products business units, broadening its product portfolio and market presence. These achievements reflect Integra Lifesciences' commitment to innovation, improving patient care, and expanding its global reach.

Integra Lifesciences Holdings Corp is a renowned global medical device company specializing in advanced surgical instruments and regenerative technologies. Established in 1989, the company has steadily evolved to become a leader in providing innovative solutions for neurosurgery, orthopedics, reconstructive surgery, and wound and tissue management. With a focus on improving patient outcomes, Integra Lifesciences develops and markets a diverse portfolio of products, ranging from implants and implants systems to surgical instruments and medical devices. Throughout its history, Integra Lifesciences has demonstrated a commitment to research, development, and collaboration, continuously enhancing its offerings to meet the evolving needs of healthcare professionals worldwide.

The main competitors of Integra Lifesciences Holdings Corp in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Baxter International Inc.

Integra Lifesciences Holdings Corp is primarily active in the healthcare and medical device industries.

The business model of Integra Lifesciences Holdings Corp is focused on providing innovative medical technologies and solutions that address various healthcare needs. The company operates in three primary segments: Codman Specialty Surgical, Orthopedics and Tissue Technologies, and Neurosurgery. Integra Lifesciences aims to enhance patient outcomes by developing and manufacturing medical devices, implants, instruments, and regenerative products. The company's comprehensive portfolio encompasses products for various medical specialties, including neurosurgery, plastic and reconstructive surgery, orthopedics, and wound care. Integra Lifesciences collaborates with healthcare professionals to offer cutting-edge solutions that improve the quality and efficiency of patient care.

P/E odnos Integra Lifesciences Holdings iznosi 10,35.

KUV kompanije Integra Lifesciences Holdings iznosi 1,48.

AlleAktien kvalitativni skor za Integra Lifesciences Holdings je 5/10.

očekivana Integra Lifesciences Holdings promet je 1,71 milijardi USD.

Dobit očekivana Integra Lifesciences Holdings je 243,96 mil. USD.

Integra Lifesciences Holdings Corp is a leading company in the field of medical devices and instruments. It offers a wide range of products and services tailored to the needs of the healthcare industry. The company operates in three main divisions: neurosurgery, plastic & reconstructive surgery, and orthopedics & cell therapy. The neurosurgery division offers a variety of products and services tailored to the needs of neurosurgeons and patients. Integra Lifesciences Holdings Corp develops and produces innovative solutions for the treatment of neurological disorders such as Parkinson's disease. The products include the neuromodulatory system, brain stimulation device, and other technologies that help treat neurological disorders. The plastic & reconstructive surgery division offers solutions for reconstructive and aesthetic surgery. The product range includes a variety of implants, tissue grafts, bone substitutes, and other products tailored to the needs of surgeons. The company works closely with doctors to provide innovative solutions that improve patients' lives. The orthopedics & cell therapy division offers products and services tailored to the needs of orthopedic surgeons and patients. The range includes a wide range of products, such as artificial joints and bone grafts. Integra Lifesciences Holdings Corp also offers innovative cell therapy solutions. In addition to the mentioned divisions, other products are available, such as maggot cultures for wound therapy. The company places great emphasis on quality and research. It continuously invests in research and development and works closely with doctors and researchers to provide innovative solutions. Integra Lifesciences Holdings Corp has a broad customer base throughout Europe and North America and works closely with doctors, clinics, and hospitals to ensure the best possible patient care. Overall, Integra Lifesciences Holdings Corp offers innovative and individual solutions in the specialized field of healthcare through its wide range of products and research.

Integra Lifesciences Holdings isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Integra Lifesciences Holdings trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Integra Lifesciences Holdings je US4579852082.

WKN od Integra Lifesciences Holdings je 897013.

Oznaka za praćenje akcija kompanije Integra Lifesciences Holdings je IART.

U poslednjih 12 meseci, Integra Lifesciences Holdings je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Integra Lifesciences Holdings će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Integra Lifesciences Holdings trenutno iznosi .

Integra Lifesciences Holdings isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Integra Lifesciences Holdings je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Integra Lifesciences Holdings se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Integra Lifesciences Holdings od 27. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 27. 7. 2024..

Isplata poslednje dividende izvršena je 27. 7. 2024..

U godini 2023 kompanija Integra Lifesciences Holdings je isplatila 0 USD kao dividende.

Dividende od Integra Lifesciences Holdings se isplaćuju u USD.